MCID: FLR001
MIFTS: 51

Filarial Elephantiasis

Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Filarial Elephantiasis

MalaCards integrated aliases for Filarial Elephantiasis:

Name: Filarial Elephantiasis 12 53 15 17
Lymphatic Filariasis 12 75 53 59 55 3 15
Elephantiasis 53 72
Filariasis 53 72
Infection by Wuchereria Bancrofti 72
Wuchereria Bancrofti Infection 53
Bancroftian Filarial Chyluria 12
Malayi Tropical Eosinphilia 53
Bancroftian Elephantiasis 12
Elephantiasis of Eyelid 12
Elephantiasis, Filarial 44
Bancroftian Filariasis 53
Filarial Elephantiases 72
Wuchereriasis 53
Elephantitis 53

Characteristics:

Orphanet epidemiological data:

59
lymphatic filariasis
Inheritance: Not applicable; Prevalence: >1/1000; Age of onset: All ages;

Classifications:

Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:12211
MeSH 44 D004605
NCIt 50 C128360
SNOMED-CT 68 91586009
ICD10 33 B74.0
ICD10 via Orphanet 34 B74.0 B74.1 B74.2
UMLS via Orphanet 73 C0013884
Orphanet 59 ORPHA2035
UMLS 72 C0013882 C0013884 C0016085 more

Summaries for Filarial Elephantiasis

NIH Rare Diseases : 53 Lymphatic filariasis is a parasitic disease caused by microscopic, thread-like worms that only live in the human lymph system, which maintains the body's fluid balance and fights infections. It is spread from person to person by mosquitoes. Most infected people are asymptomatic and never develop clinical symptoms. A small percentage of people develop lymphedema, which may affect the legs, arms, breasts, and genitalia; bacterial infections that cause hardening and thickening of the skin, called elephantiasis; hydrocele (swelling of the scrotum) in men; and pulmonary tropical eosinophilia syndrome. Treatment may include a yearly dose of medicine, called diethylcarbamazine (DEC); while this drug does not kill all of the adult worms, it prevents infected people from giving the disease to someone else.

MalaCards based summary : Filarial Elephantiasis, also known as lymphatic filariasis, is related to loiasis and intestinal volvulus, and has symptoms including chyluria An important gene associated with Filarial Elephantiasis is IL10 (Interleukin 10), and among its related pathways/superpathways are IL-17 Family Signaling Pathways and Th17 cell differentiation. The drugs Diethylcarbamazine and Doxycycline have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and testes.

Disease Ontology : 12 A filariasis that is characterized by the thickening of the skin and underlying tissues, especially in the legs, male genitals and female breasts, caused by thread-like parasitic worms Wuchereria bancrofti, Brugia malayi or Brugia timori, which inhabit the lymphatics. These nematodes are transmitted by mosquitoes. Acute symptoms include fever, lymphadenitis, lymphangitis, funiculitis, and epididymitis. Chronic symptoms include abscesses, hyperkeratosis, polyarthritis, hydroceles, lymphedema, and elephantiasis.

CDC : 3 Lymphatic filariasis, considered globally as a neglected tropical disease (NTD), is a parasitic disease caused by microscopic, thread-like worms. The adult worms only live in the human lymph system. The lymph system maintains the body's fluid balance and fights infections. Lymphatic filariasis is spread from person to person by mosquitoes. People with the disease can suffer from lymphedema and elephantiasis and in men, swelling of the scrotum, called hydrocele. Lymphatic filariasis is a leading cause of permanent disability worldwide. Communities frequently shun and reject women and men disfigured by the disease. Affected people frequently are unable to work because of their disability, and this harms their families and their communities.

Wikipedia : 75 Lymphatic filariasis, also known as elephantiasis, is a human disease caused by parasitic worms known as... more...

Related Diseases for Filarial Elephantiasis

Diseases related to Filarial Elephantiasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 471)
# Related Disease Score Top Affiliating Genes
1 loiasis 33.6 SRCIN1 MFF IL10
2 intestinal volvulus 31.7 SRCIN1 IL5
3 elephantiasis 31.5 SRCIN1 MFF GPT2
4 ascaridiasis 31.2 STH IL10
5 schistosomiasis 31.1 IL5 IL4 IL10
6 endomyocardial fibrosis 31.0 IL4 IL10
7 coccidioidomycosis 30.8 TLR4 IL10
8 trichuriasis 30.7 STH IL10
9 allergic hypersensitivity disease 30.5 IL5 IL4 IL10
10 trichinosis 30.4 IL5 IL4
11 poliomyelitis 30.4 IL4 IL10
12 urinary schistosomiasis 30.3 IL5 IL4
13 angiostrongyliasis 30.2 IL5 IL4
14 cystic echinococcosis 30.2 TLR4 IL10
15 ige responsiveness, atopic 30.2 IL5 IL4 IL10
16 tetanus 30.1 IL5 IL4 IL10
17 buruli ulcer 30.1 IL4 IL10
18 trypanosomiasis 30.0 TLR2 IL4 IL10
19 bacterial infectious disease 29.9 TLR4 TLR2 IL10
20 dermatitis, atopic 29.9 IL5 IL4 IL10
21 intestinal schistosomiasis 29.8 SRCIN1 IL5 IL4
22 filariasis 29.8 TLR4 TLR2 IL5 IL10
23 chagas disease 29.5 TLR4 TLR2 IL10
24 parasitic protozoa infectious disease 29.5 TLR2 IL4 IL10
25 pulmonary tuberculosis 29.5 TLR2 IL4 IL10
26 lung disease 29.4 TLR2 IL5 IL10
27 malaria 29.2 TLR4 TLR2 IL5 IL4 IL10
28 echinococcosis 29.1 TLR4 TLR2 IL5 IL10
29 chlamydia 29.0 TLR4 TLR2 IL4 IL10
30 skin disease 29.0 IL5 IL4 IL10
31 leishmaniasis 29.0 TLR4 TLR2 IL5 IL4 IL10
32 visceral leishmaniasis 28.8 TLR4 TLR2 IL4 IL10
33 toxic shock syndrome 28.7 TLR4 TLR2 IL4 IL10
34 parasitic helminthiasis infectious disease 28.6 STH SRCIN1 MFF IL5 IL4 IL10
35 toxoplasmosis 28.6 TLR4 TLR2 IL4 IL10
36 mycobacterium tuberculosis 1 28.6 TLR4 TLR2 IL4 IL10
37 rheumatoid arthritis 28.5 TLR4 TLR2 IL4 IL10
38 cutaneous leishmaniasis 28.1 TLR4 TLR2 IL5 IL4 IL10
39 proteasome-associated autoinflammatory syndrome 1 28.1 TLR4 TLR2 IL5 IL4 IL10
40 podoconiosis 11.9
41 dirofilariasis 11.8
42 mansonelliasis 11.7
43 onchocerciasis 11.6
44 dipetalonemiasis 11.5
45 setariasis 11.2
46 lymphedema 10.8
47 hypereosinophilic syndrome 10.8
48 cephalosporin allergy 10.6 IL5 IL10
49 lymphangitis 10.6
50 necatoriasis 10.6 IL5 IL10

Graphical network of the top 20 diseases related to Filarial Elephantiasis:



Diseases related to Filarial Elephantiasis

Symptoms & Phenotypes for Filarial Elephantiasis

UMLS symptoms related to Filarial Elephantiasis:


chyluria

Drugs & Therapeutics for Filarial Elephantiasis

Drugs for Filarial Elephantiasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 4 90-89-1 3052
2
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
3 Lipoxygenase Inhibitors Phase 4
4 Anti-Bacterial Agents Phase 4
5 Antimalarials Phase 4
6
Petrolatum Approved, Investigational Phase 3 8009-03-8
7
Glycerol Approved, Investigational Phase 3 56-81-5 753
8 Disinfectants Phase 3
9 Sodium hypochlorite Phase 3
10 Protective Agents Phase 3
11 Eusol Phase 3
12 Vitamins Phase 3
13 Reslizumab Approved, Investigational Phase 2
14
Dihydroartemisinin Experimental, Investigational Phase 2 71939-50-9 6918483
15
Piperaquine Experimental, Investigational Phase 2 4085-31-8 5079497
16 Artemisinins Phase 2
17 Artemisinine Phase 2
18 Antibodies Phase 2
19 Respiratory System Agents Phase 2
20 Immunoglobulins Phase 2
21 Anti-Asthmatic Agents Phase 2
22 Antibodies, Monoclonal Phase 2
23 Imatinib Mesylate Phase 2 220127-57-1 123596
24 Protein Kinase Inhibitors Phase 2
25
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
26
Emodepside Investigational, Vet_approved Phase 1 155030-63-0
27 Pharmaceutical Solutions Phase 1
28
Polidocanol Approved 9002-92-0
29
Sodium citrate Approved, Investigational 68-04-2
30
Mebendazole Approved, Vet_approved 31431-39-7 4030
31
Piperazine Approved, Vet_approved 110-85-0 4837
32
Permethrin Approved, Investigational 52645-53-1 40326
33
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
34 Sclerosing Solutions
35 Anesthetics
36 Citrate
37 DMP 777 157341-41-8
38 Piperazine citrate
39 Liver Extracts
40 Insect Repellents

Interventional clinical trials:

(show top 50) (show all 62)
# Name Status NCT ID Phase Drugs
1 Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali Completed NCT02784743 Phase 4 ''albendazole'' and ''ivermectin''
2 Comparison Between the Post-Treatment Reactions After Single-dose Ivermectin or DEC in Subjects With Loa Loa Infection Completed NCT01593722 Phase 4 Diethylcarbamazine;Ivermectin
3 Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration Completed NCT02005653 Phase 4 Diethylcarbamazine;Albendazole;Doxycycline
4 Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations Recruiting NCT03036059 Phase 4 400 μg/kg Ivermectin + 400 mg Albendazole
5 Safety of the Co-administration of Azithromycin, Albendazole and Ivermectin Versus Standard Treatment Regimens During Mass Drug Administration (MDA) in Ethiopia: a Cluster-randomized Trial Not yet recruiting NCT03570814 Phase 4 Administration of Albendazole on Day 1;Administration of Ivermectin on Day 1;Administration of Azithromycin on Day 1;Administration of Azithromycin on Day 15
6 AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole Withdrawn NCT01903057 Phase 4 azithromycin;ivermectin;albendazole;placebo
7 Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study Withdrawn NCT02734186 Phase 4 Praziquantel
8 A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia Completed NCT02839772 Phase 3
9 Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Completed NCT02509481 Phase 2, Phase 3 Ivermectin;Albendazole
10 A Cluster Randomised Trial of the Safety of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03676140 Phase 3 Albendazole on Day 1;Ivermectin on Day 1;Diethylcarbamazine on day 1;Azithromycin on Day 1;Azithromycin on Day 8
11 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
12 Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH) Recruiting NCT03014167 Phase 3 Albendazole
13 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929134 Phase 3 Doxycycline;Placebo
14 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02929121 Phase 3 Doxycycline;Placebo
15 A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection Active, not recruiting NCT02927496 Phase 3 Doxycycline;Placebo
16 Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa Completed NCT01975441 Phase 2 Diethylcarbamazine;Albendazole;Ivermectin
17 Effect of Albendazole and Ivermectin Dose on Wuchereria Bancrofti Microfilarial Clearance in Mali: A Randomized, Open Label Study Completed NCT00339417 Phase 2 Albendazole;Ivermectin
18 Effect of Albendazole Dose and Interval on Wuchereria Bancrofti Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00375583 Phase 2 DEC/Albendazole
19 A Pharmacokinetic and Pharmacodynamic Evaluation of Co-Administration of IDA (Ivermectin, Diethylcarbamazine and Albendazole) & Azithromycin for Integrated Treatment of Neglected Tropical Diseases Completed NCT03664063 Phase 2 Azithromycin;Albendazole;Ivermectin;Diethylcarbamazine
20 Effect of Albendazole Dose and Interval on Brugia Malayi Microfilarial Clearance in India: A Randomized, Open Label Study Completed NCT00511004 Phase 2 Albendazole;Diethylcarbamazine
21 Treatment of Mansonella Perstans Infection in an Area Coendemic for Lymphatic Filariasis: A Pilot Study of the Effects of Doxycycline Completed NCT00340691 Phase 2 Doxycycline
22 Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL) Completed NCT02511353 Phase 2 ivermectin;placebo;dihydroartemisinin-piperaquine
23 A Randomized, Placebo-controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection Completed NCT01111305 Phase 2 Reslizumab;Diethylcarbamazine
24 Study on Selective Pelvic Lymphadenectomy for IB-IIA Cervical Cancer Recruiting NCT03295526 Phase 2
25 A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa (A Pilot Study) Not yet recruiting NCT02644525 Phase 2 Imatinib Mesylate;Placebo
26 Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire Completed NCT02845713 Phase 1 Ivermectin, Diethylcarbamazine Albendazole (IDA)
27 A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT03383614 Phase 1 LSF emodepside (BAY 44-4400) oral solution (1mg/mL)
28 A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects Completed NCT02661178 Phase 1 emodepside (BAY 44-4400);placebo
29 Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects Completed NCT03383523 Phase 1 Emodepside (BAY 44-4400)
30 Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study. Unknown status NCT02082613
31 Research for Elimination of Lymphatic Filariasis (ICIDR) Completed NCT00406627
32 Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India Completed NCT01629771
33 A Pharmacovigilance Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults Living in the Sikasso Region of Mali Completed NCT01586169 triple co administration at once of the combination of Albendazole + ivermectin + azithromycin
34 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis Completed NCT02899936 3 drug dose - IDA;2 drug dose - DA
35 Studies on the Interaction Between HIV Infection, Lymphatic Filariasis and Diethylcarbamazine Completed NCT00295698 Diethylcarbamazine
36 Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire] Completed NCT02974049 Albendazole;Ivermectin;Diethylcarbamazine
37 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea Completed NCT03268252
38 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole and diethylcarbamazine
39 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
40 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Completed NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
41 Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji Completed NCT03177993 3 drug dose - IDA;3 drug dose - IDA with second dose of ivermectin;2 drug dose - DA
42 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
43 Evaluation of Antibacterial Soap for Treatment of Lymphedema and Elephantiasis in an Area Endemic for Lymphatic Filariasis Completed NCT00139100 antimicrobial agent in soap
44 Promoting Consistent Shoe Use Among Children At High Risk for Podoconiosis Completed NCT01160523
45 Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications Completed NCT00471666
46 Research for Elimination of Human Filariasis Completed NCT00145223
47 Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites Completed NCT00341666
48 Exhaled NO Testing in Filariasis Completed NCT01628497
49 Gaps in Helminth Control: Safety and Efficacy of Drug Combinations Against Triple Infections Completed NCT01050517 albendazole + ivermectin + praziquantel;albendazole + ivermectin + (1 week later) praziquantel
50 Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection Completed NCT00344279

Search NIH Clinical Center for Filarial Elephantiasis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Ivermectin

Cochrane evidence based reviews: elephantiasis, filarial

Genetic Tests for Filarial Elephantiasis

Anatomical Context for Filarial Elephantiasis

MalaCards organs/tissues related to Filarial Elephantiasis:

41
Skin, Breast, Testes, T Cells, Monocytes, Endothelial, Lymph Node

Publications for Filarial Elephantiasis

Articles related to Filarial Elephantiasis:

(show top 50) (show all 2572)
# Title Authors PMID Year
1
Regulation of parasite antigen-driven immune responses by interleukin-10 (IL-10) and IL-12 in lymphatic filariasis. 9 38
9125556 1997
2
Immunoregulation in human lymphatic filariasis: the role of interleukin 10. 9 38
7501419 1995
3
Antifilarial activity of azadirachtin fuelled through reactive oxygen species induced apoptosis: a thorough molecular study on Setaria cervi. 38
30032733 2019
4
EBM verdict: should albendazole be used for treating lymphatic filariasis? No. 38
30971416 2019
5
Development of an Antigen Detection ELISA for Bancroftian Filariasis Using BmSXP-Specific Recombinant Monoclonal Antibody. 38
31162018 2019
6
Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt. 38
31400299 2019
7
Correction to: How Thailand eliminated lymphatic filariasis as a public health problem. 38
31420004 2019
8
Lessons from lymphatic filariasis elimination and the challenges of post-elimination surveillance in China. 38
31387644 2019
9
Transcriptomic analysis of insecticide resistance in the lymphatic filariasis vector Culex quinquefasciatus. 38
31388075 2019
10
The Elimination of Neglected Tropical Diseases (NTDs): A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions. 38
31402376 2019
11
Wuchereria bancrofti infection is linked to systemic activation of CD4 and CD8 T cells. 38
31425508 2019
12
Ivermectin: From theory to clinical application. 38
31071469 2019
13
Progress towards lymphatic filariasis elimination in Ghana from 2000-2016: Analysis of microfilaria prevalence data from 430 communities. 38
31398203 2019
14
Immune Response to Brugia malayi Asparaginyl-tRNA Synthetase in Balb/c Mice and Human Clinical Samples of Lymphatic Filariasis. 38
30570354 2019
15
The impact of acute adenolymphangitis in podoconiosis on caregivers: A case study in Wayu Tuka woreda, Oromia, Western Ethiopia. 'If she was healthy, I would be free.' 38
31283763 2019
16
Eliminating lymphatic filariasis - Is it worth it? 38
31343066 2019
17
Self-reactive IgG4 antibodies are associated with blocking of pathology in human lymphatic filariasis. 38
31130239 2019
18
Improved assessment of mass drug administration and health district management performance to eliminate lymphatic filariasis. 38
31276494 2019
19
The health and economic burden of lymphatic filariasis prior to mass drug administration programmes. 38
31343064 2019
20
Dosing pole recommendations for lymphatic filariasis elimination: A height-weight quantile regression modeling approach. 38
31314753 2019
21
Ecological and Socioeconomic Predictors of Transmission Assessment Survey Failure for Lymphatic Filariasis. 38
31115301 2019
22
Developing the first national database and map of lymphatic filariasis clinical cases in Bangladesh: Another step closer to the elimination goals. 38
31306409 2019
23
Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis. 38
31260444 2019
24
Production optimization and biosynthesis revision of corallopyronin A, a potent anti-filarial antibiotic. 38
31340171 2019
25
Soil-transmitted helminth infection in school age children in Sierra Leone after a decade of preventive chemotherapy interventions. 38
31262367 2019
26
Lymphatic Filariasis. 38
31027660 2019
27
Neglected Tropical Diseases: The Potential Application to Monitoring by microRNAs in the Real World. 38
31218967 2019
28
Prevalence of Neglected Tropical Diseases (Leishmaniasis and Lymphatic Filariasis) and Malaria Among a Migrant Labour Settlement in Kerala, India. 38
29860672 2019
29
The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study. 38
31233507 2019
30
Bridging the gap in outreach and compliance with mass drug administration for lymphatic filariasis elimination in an endemic district in Kerala, India: an intervention research approach. 38
30805648 2019
31
GEOFIL: A spatially-explicit agent-based modelling framework for predicting the long-term transmission dynamics of lymphatic filariasis in American Samoa. 38
30611745 2019
32
A detailed review of the mosquitoes (Diptera: Culicidae) of Iran and their medical and veterinary importance. 38
30898616 2019
33
Development of a High-Throughput Cytometric Screen to Identify Anti- Wolbachia Compounds: The Power of Public-Private Partnership. 38
30958712 2019
34
Strategies to Control Human Lymphatic Filarial Infection: Tweaking Host's Immune System. 38
31244425 2019
35
New HPLC-MS method for rapid and simultaneous quantification of doxycycline, diethylcarbamazine and albendazole metabolites in rat plasma and organs after concomitant oral administration. 38
30947125 2019
36
Troponin 1 of human filarial parasite Brugia malayi: cDNA cloning, expression, purification, and its immunoprophylactic potential. 38
31055672 2019
37
In Vitro And In Vivo Antifilarial Activity Of Standardized Extract Of Calotropis procera Flowers Against Brugia malayi. 38
31218959 2019
38
Discovery of Kirromycins with Anti- Wolbachia Activity from Streptomyces sp. CB00686. 38
31074963 2019
39
In Vitro and In Silico Studies of Glycyrrhetinic acid derivatives as Anti-Filarial Agents. 38
31210109 2019
40
Genomic analyses of aminoacyl tRNA synthetases from human-infecting helminths. 38
31046663 2019
41
Evaluation of lymphatic filariasis in endemic area of Brazil where mass drug administration is not required. 38
31138026 2019
42
Prevalence of malaria and lymphatic filariasis in bateyes of the Dominican Republic. 38
31130142 2019
43
How Thailand eliminated lymphatic filariasis as a public health problem. 38
31130143 2019
44
Novel odor-based strategies for integrated management of vectors of disease. 38
31247410 2019
45
Human Migration and the Spread of the Nematode Parasite Wuchereria bancrofti. 38
31077328 2019
46
Assessment of treatment impact on lymphatic filariasis in 13 districts of Benin: progress toward elimination in nine districts despite persistence of transmission in some areas. 38
31146779 2019
47
Development and application of a tri-allelic PCR assay for screening Vgsc-L1014F kdr mutations associated with pyrethroid and organochlorine resistance in the mosquito Culex quinquefasciatus. 38
31088572 2019
48
Influence of seasonal variation on reported filarial attacks among people living with lymphedema in Ghana. 38
31109288 2019
49
Wuchereria bancrofti-infected individuals harbor distinct IL-10-producing regulatory B and T cell subsets which are affected by anti-filarial treatment. 38
31120872 2019
50
Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d'Ivoire. 38
31107869 2019

Variations for Filarial Elephantiasis

Expression for Filarial Elephantiasis

Search GEO for disease gene expression data for Filarial Elephantiasis.

Pathways for Filarial Elephantiasis

Pathways related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 TLR2 IL5 IL4
2
Show member pathways
12.09 TLR4 TLR2 IL5 IL4 IL10
3 11.98 TLR4 TLR2 IL10
4
Show member pathways
11.93 TLR4 TLR2 IL4
5
Show member pathways
11.9 TLR4 TLR2 IL4 IL10
6
Show member pathways
11.81 TLR4 TLR2 IL10
7
Show member pathways
11.79 TLR4 TLR2 IL4
8
Show member pathways
11.76 TLR4 TLR2 IL5
9 11.72 IL5 IL4 IL10
10 11.64 TLR4 TLR2 IL10
11 11.51 IL5 IL4 IL10
12 11.38 IL5 IL4 IL10
13 11.23 TLR4 TLR2 IL10
14 11.14 TLR4 IL10
15 11.1 IL5 IL4 IL10
16 11.09 IL5 IL4
17 11.07 IL5 IL4
18 10.96 IL5 IL4 IL10
19 10.59 IL5 IL4 IL10
20 10.21 IL5 IL4 IL10

GO Terms for Filarial Elephantiasis

Biological processes related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.81 TLR4 TLR2 IL5 IL10
2 immune response GO:0006955 9.77 TLR4 TLR2 IL5 IL4 IL10
3 response to lipopolysaccharide GO:0032496 9.74 TLR4 TLR2 IL10
4 negative regulation of endothelial cell apoptotic process GO:2000352 9.62 IL4 IL10
5 lipopolysaccharide-mediated signaling pathway GO:0031663 9.62 TLR4 TLR2
6 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.61 TLR4 TLR2
7 negative regulation of interleukin-6 production GO:0032715 9.61 TLR4 IL10
8 negative regulation of interferon-gamma production GO:0032689 9.6 TLR4 IL10
9 positive regulation of interleukin-8 production GO:0032757 9.59 TLR4 TLR2
10 positive regulation of interferon-beta production GO:0032728 9.58 TLR4 TLR2
11 positive regulation of interleukin-12 production GO:0032735 9.58 TLR4 TLR2
12 positive regulation of interleukin-10 production GO:0032733 9.56 TLR4 TLR2
13 negative regulation of osteoclast differentiation GO:0045671 9.55 TLR4 IL4
14 positive regulation of chemokine production GO:0032722 9.54 TLR4 TLR2
15 positive regulation of macrophage activation GO:0043032 9.52 TLR4 IL10
16 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.49 TLR4 TLR2
17 response to molecule of bacterial origin GO:0002237 9.46 TLR2 IL10
18 I-kappaB phosphorylation GO:0007252 9.43 TLR4 TLR2
19 cellular response to lipoteichoic acid GO:0071223 9.4 TLR4 TLR2
20 positive regulation of B cell proliferation GO:0030890 9.33 TLR4 IL5 IL4
21 type 2 immune response GO:0042092 9.32 IL4 IL10
22 regulation of isotype switching GO:0045191 9.26 IL4 IL10
23 regulation of cytokine secretion GO:0050707 9.18 TLR2
24 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 8.96 TLR4 TLR2
25 positive regulation of MHC class II biosynthetic process GO:0045348 8.8 TLR4 IL4 IL10

Molecular functions related to Filarial Elephantiasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 IL5 IL4 IL10
2 lipopolysaccharide binding GO:0001530 9.16 TLR4 TLR2
3 growth factor activity GO:0008083 9.13 IL5 IL4 IL10
4 lipopolysaccharide receptor activity GO:0001875 8.62 TLR4 TLR2

Sources for Filarial Elephantiasis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....